Nijmegen Antihypertensive Management Improvement Study
NCT00457483
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Primary Hypertension
Interventions
DRUG:
hydrochlorothiazide
DRUG:
valsartan, 80 mg once-a-day
Sponsor
Radboud University Medical Center